Ticker >

Ind-Swift share price

Ind-Swift Ltd.

NSE: INDSWFTLTD BSE: 524652 SECTOR: Pharmaceuticals & Drugs  21k   19   1

20.10
-1.52 (-7.03%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 21.19

Today's Low

₹ 19.61

52 Week High

₹ 31.09

52 Week Low

₹ 14.4

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

108.87 Cr.

Enterprise Value

1059.73 Cr.

No. of Shares

5.42 Cr.

P/E

2.71

P/B

0

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  -122.33

CASH

63.14 Cr.

DEBT

1014 Cr.

Promoter Holding

55.58 %

EPS (TTM)

₹  7.4

Sales Growth

22.21%

ROE

0 %

ROCE

25.99%

Profit Growth

-45.34 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.21%
3 Year12.15%
5 Year11.68%

Profit Growth

1 Year-45.34%
3 Year35.31%
5 Year11.68%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year25.99%
3 Year22.04%
5 Year15.83%

Debt/Equity

-1.4678

Price to Cash Flow

7.12

Interest Cover Ratio

1.2616

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2024 55.58 42.81
Mar 2024 55.58 42.81
Dec 2023 55.58 42.81
Sep 2023 55.58 42.81
Jun 2023 55.58 42.81
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 35.3089245833809% for the Past 3 years.
  • Company has been maintaining healthy ROCE of 22.0395029153169% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of -141.8117 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 14.6132040113354.

 Limitations

  • The company has shown a poor revenue growth of 12.1496810975214% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Tax rate is low at 13.5585.
  • The company has negative book value.
  • Promoter pledging is high as 42.81%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 148.54 115.92 102.56 135.23 113.85
Total Expenditure 130.14 104.78 98.07 120.75 110.63
Operating Profit 18.4 11.14 4.49 14.49 3.22
Other Income 5.63 3.15 2.62 46.59 39.93
Interest 14.95 18.27 15.3 14.43 9.54
Depreciation 6.72 6.73 6.78 6.88 5.37
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.36 -10.71 -14.97 39.77 28.24
Tax 0 0 0 2.23 0
Profit After Tax 2.36 -10.71 -14.97 37.54 28.24
Adjusted EPS (Rs) 0.44 -1.98 -2.76 6.93 5.21

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 329.52 356.06 397.71 410.96 502.25
Total Expenditure 306.18 314.68 352.36 368.93 453.73
Operating Profit 23.34 41.37 45.35 42.03 48.51
Other Income 22.38 15.22 23.55 11.85 57.99
Interest 35.19 52.18 57.16 59.76 62.94
Depreciation 33.59 32.7 32.07 28.67 27.11
Exceptional Items 6.4 -1.21 0.73 60.58 0
Profit Before Tax -16.66 -29.49 -19.6 26.04 16.46
Tax 2.46 0.32 0.42 0 2.23
Net Profit -19.12 -29.82 -20.02 26.04 14.23
Adjusted EPS (Rs.) -3.53 -5.5 -3.7 4.81 2.63

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10.83 10.83 10.83 10.83 10.83
Total Reserves -723.95 -706 -731.15 -715.53 -701.66
Borrowings 644.21 644.17 619.3 403.11 1009.5
Other N/C liabilities 16.42 16.41 14.76 14.47 15.43
Current liabilities 654.13 706.16 718.03 936.33 320.37
Total Liabilities 601.65 671.57 631.76 649.21 654.47
Assets
Net Block 269.66 244.01 235.5 216.46 184.05
Capital WIP 0 13.06 9 29.73 51.24
Intangible WIP 0 0 0 0 0
Investments 24.06 70.31 64.35 53.73 1.26
Loans & Advances 79.27 79.02 80.46 75.9 76.13
Other N/C Assets 0 0 0 0 0
Current Assets 228.65 265.17 242.44 273.38 341.79
Total Assets 601.65 671.57 631.76 649.21 654.47
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -19.12 -28.29 -20.34 -34.54 16.46
Adjustment 52.68 88.12 77.94 85.23 45.92
Changes in Assets & Liabilities 1.03 23.68 -6.98 22.36 -47.1
Tax Paid 0 -0.32 -0.42 0 0
Operating Cash Flow 34.6 83.19 50.2 73.05 15.28
Investing Cash Flow -11.35 -16.71 -18.42 -29.35 76.61
Financing Cash Flow -26.2 -54.25 -44.6 -46.56 -42.08
Net Cash Flow -2.96 12.23 -12.81 -2.85 49.81

Corporate Actions

Investors Details

PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
promoters 55.58 55.58 55.58 55.58 55.58
annie mehta 0.29 0.29 0.29 0.29 0.29
bhanavi mehta 0.06 0.06 0.06 0.06 0.06
deepti munjal 0.06 0.06 0.06 0.06 0.06
divya munjal 0.03 0.03 0.03 0.03 0.03
essix biosciences limited... 31.45 31.45 31.45 31.45 31.45
gopal munjal 3.61 3.61 3.61 3.61 3.61
himanshu jain 0.91 0.91 0.91 0.91 0.91
ishav mehta 0.08 0.08 0.08 0.08 0.08
meenakshi mehta 0.74 0.74 0.74 0.74 0.74
n.r. munjal 1.13 1.13 1.13 1.13 1.13
neera mehta 2.86 2.86 2.86 2.86 2.86
neeta munjal 1.07 1.07 1.07 1.07 1.07
nidhi munjal 0.93 0.93 0.93 0.93 0.93
ravi mehta 1.17 1.17 1.17 1.17 1.17
rishav mehta 0.21 0.21 0.21 0.21 0.21
s. r. mehta 3.76 3.76 3.76 3.76 3.76
sahil munjal 0.24 0.24 0.24 0.24 0.24
saurabh munjal 0.10 0.10 0.10 0.10 0.10
sunita jain 3.35 3.35 3.35 3.35 3.35
v.r. mehta 3.55 3.55 3.55 3.55 3.55
PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
investors 44.42 44.42 44.42 44.42 44.42
deepa ram kheria 1.57 1.57 - 1.55 1.55
excel motors private limi... 1.08 1.08 1.08 1.08 1.08
gravity systems private l... 1.38 1.38 1.38 1.38 1.38
investor education and pr... 0.90 - - 0.90 0.90
justin pharmaceuticals pr... 1.59 1.59 1.59 1.59 1.59
panchkula finvest private... 1.31 1.31 1.31 1.31 1.31
rameshkumar javerchand ja... 1.76 1.77 1.77 1.77 1.98
sharwan singh guleria 1.94 1.94 1.93 1.90 1.90
investor education and pr... - 0.90 0.90 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

IND Swift informs about closure of trading window28 Sep 2024, 3:37PM Ind-Swift informs about newspaper publication29 Aug 2024, 2:38PM Ind-Swift - Quaterly Results13 Aug 2024, 6:52PM Ind-Swift - Quaterly Results14 May 2024, 7:44PM Ind-Swift - Quaterly Results14 May 2024, 7:44PM Ind-Swift submits board meeting intimation 2 May 2024, 2:04PM Ind-Swift - Quaterly Results14 Feb 2024, 7:25PM Ind-Swift informs about press release15 Feb 2023, 2:47PM Ind-Swift informs about newspaper publication16 Nov 2022, 3:19PM Ind-Swift informs about AGM outcome22 Sep 2022, 2:41PM Ind-Swift informs about reappointment of statutory auditor22 Sep 2022, 2:36PM Ind-Swift informs about change in directorate22 Sep 2022, 2:32PM Ind Swift informs about annual report and AGM notice27 Aug 2022, 2:48PM Ind-Swift informs about newspaper publication25 Aug 2022, 1:48PM Ind-Swift - Quaterly Results9 Aug 2022, 6:06PM Ind-Swift - Quaterly Results9 Aug 2022, 6:06PM Ind-Swift launches cardio diabetic & antibiotic products in Qatar3 Jun 2022, 4:26PM Ind-Swift incorporates wholly owned subsidiary company16 May 2022, 10:00AM Ind-Swift informs about compliance certificate25 Apr 2022, 12:24PM Ind-Swift informs about compliance certificate11 Jan 2022, 4:47PM Ind-Swift informs about outcome of board meeting19 Aug 2021, 12:07PM Ind-Swift informs about certificate8 Jul 2021, 3:28PM Ind-Swift informs about annual secretarial compliance report 3 Jun 2021, 4:36PM Ind-Swift informs about non-applicability of large corporate entity27 Apr 2021, 3:51PM

Ind-Swift Stock Price Analysis and Quick Research Report. Is Ind-Swift an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ind-Swift and its performance over the period of time. Ind-Swift stock price today is Rs 19.89.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ind-Swift cash from the operating activity was Rs 15.2828 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ind-Swift has a Debt to Equity ratio of -1.4678 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ind-Swift , the EPS growth was -45.3422 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ind-Swift has OPM of 9.65929759359773 % which is a bad sign for profitability.
     
  • ROE: Ind-Swift have a poor ROE of 0 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ind-Swift is Rs 19.89. One can use valuation calculators of ticker to know if Ind-Swift share price is undervalued or overvalued.
Last Updated on:
Brief about Ind-Swift
X